Skip to main content

Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study

Completed · NCT05991323

Conditions: Prurigo Nodularis

At a glance

Research payments reported, 2025
$249,277
U.S. investigators named
25
Sites paid
27
Planned or actual enrollment
110

About the trial

Sponsor
Sanofi (with Regeneron Pharmaceuticals)
Tested
Dupilumab (drug)
Dates
Started 2023-12-12; completion 2026-09-08
Results posted
Not yet

This study is a prospective, multinational, observational investigation designed to elucidate the real-world effectiveness and treatment patterns of dupilumab therapy in adult patients diagnosed with prurigo nodularis (PN). The primary objective of this study is to comprehensively characterize the real-world usage of dupilumab for the management of PN. In addition to this, the study aims to achieve several secondary objectives, including a detailed assessment of the medical history, socio-demographic and disease characteristics of dupilumab-treated PN patients, as well as the evaluation of the long-term real-world effectiveness of dupilumab therapy for PN.

From ClinicalTrials.gov, last updated 2026-10-01. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sanofi US Services Inc. reported $249,277 in research payments for this study in 2025 (126 payments).

Products named: Dupixent

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Dermatology Skin Cancer Specialists PA $44,392
  • Golden State Dermatology Associates Inc $29,336
  • The Board of Regents of the University of Nebraska $22,185
  • The Derm Institute of West Michigan Plc $20,480
  • Duke University Department of Medicine Clinical Res $16,000
  • Shireen V Guide MD Inc Mission Dermatology Center $11,147
  • Probity Medical Research Corp $10,821
  • Private Diagnostic Clinic $9,200
  • Center for Dermatology Clinical Research Inc $9,073
  • Dawes Fretzin Clinical Research Gro LLC $8,814
  • Dermatology Associates of West Michigan $8,000
  • $6,719
  • Southwest Skin Specialists Llc $6,664
  • Cr Services Acquisition Us Llc $6,582
  • Las Vegas Dermatology PC $6,261
  • Medical University of South Carolina $5,601
  • Medical University of South Carolina Health Neurology $5,025
  • Quality Clinical Research Inc $3,659
  • West Virginia Research Institute PLLC $3,570
  • Apex Clinical Research Center Llc $3,000
  • Katherine Bao Shian Lee MD A Professional Corporation Halcyon Dermatology $2,238
  • Total Vein and Skin, Llc $2,000
  • Gsi Clinical Research $2,000
  • First Oc Dermatology Research Inc $2,000
  • Medical University of South Carolina Att To Elizabeth Gossen $2,000
  • North Texas Center for Clinical Research $1,000
  • Oakland Hills Dermatology PC $878
  • Ttuhsccme $635

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.